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Abstract: Obesity, a chronic metabolic disorder, is characterized by enlarged fat mass and 
dysregulation of lipid metabolism. The medicinal plant, Boesenbergia pandurata (Roxb.) 
Schltr.,  has  been  reported  to  possess  anti-oxidative  and  anti-inflammatory  properties; 
however,  its  anti-obesity  activity  is  unexplored.  The  present  study  was  conducted  to 
determine whether B. pandurata extract (BPE), prepared from its rhizome parts, attenuated 
high-fat diet (HFD)-induced obesity in C57BL/6J mice. The molecular mechanism was 
investigated  in  3T3-L1  adipocytes  and  HepG2  human  hepatoma  cells.  BPE  treatment 
decreased triglyceride accumulation in both 3T3-L1 adipocytes and HepG2 hepatocytes by 
activating AMP-activated protein kinase (AMPK) signaling and regulating the expression 
of  lipid  metabolism-related  proteins.  In  the  animal  model,  oral  administration  of  BPE 
(200 mg/kg/day for 8 weeks) significantly reduced HFD-induced body weight gain without 
altering the amount of food intake. In addition, elevated serum levels of total cholesterol, 
low-density  lipoprotein  cholesterol,  and  triglycerides  were  suppressed  by  BPE 
administration. Fat pad masses were reduced in BPE-treated mice, as evidenced by reduced 
adipocyte size. Furthermore, BPE protected against the development of nonalcoholic fatty 
liver by decreasing hepatic triglyceride accumulation. BPE also activated AMPK signaling 
and altered the expression of lipid metabolism-related proteins in white adipose tissue and 




liver. Taken together, these findings indicate that BPE attenuates HFD-induced obesity by 
activating AMPK and regulating lipid metabolism, suggesting a potent anti-obesity agent. 
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accumulation; AMP-activated protein kinase 
 
1. Introduction  
Obesity is a chronic metabolic disorder caused by an energy imbalance. A long-term excess of 
energy intake over energy expenditure results in the storage of excess energy as fat [1,2]. Obesity is 
characterized  by  enlarged  fat  mass  and  dysregulation  of  lipid  metabolism  [3].  Hyperlipidemia  is 
caused by dysregulation of lipid metabolism, is a critical feature of obesity, and is strongly related to 
metabolic disorders [4]. Therefore, improving lipid metabolism is one of the most important strategies 
for obesity prevention and treatment [5]. 
Lipid metabolism is a crucial contributor to the pathogenesis of obesity [6]. Circulating free fatty 
acids (FFAs) are taken up by adipose, liver, and muscle tissues, where they are metabolized or stored 
as triglycerides (TGs) via the mitochondrial fatty acid oxidation (FAO) or lipid synthesis pathways [7]. 
Lipogenic proteins, including acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), stearoyl-CoA 
desaturase  (SCD),  and  peroxisome  proliferator-activated  receptor  γ  (PPARγ),  are  expressed 
predominantly  in  adipocytes  and  hepatocytes.  These  proteins  are  upregulated  by  sterol  regulatory 
element-binding  protein 1c  (SREBP-1c), which is  a  key  transcription factor upregulating  de  novo 
lipogenesis [8]. The increased expression of certain lipogenic proteins significantly elevates circulating 
FFAs and cholesterol, which results in insulin resistance. However, proteins, such as PPARʱ, carnitine 
palmitoyl  transferase  1  (CPT-1),  and  uncoupling  proteins  (UCPs),  increase  FAO  and  fatty  acid 
clearance. In mice, downregulating lipogenic proteins and upregulating FAO proteins attenuate obesity 
and dyslipidemia in the high-fat diet (HFD)-induced obese rodent model [5,9–11]. 
AMP-activated protein kinase (AMPK) functions as a key energy sensor and is activated by energy 
depletion. Once activated, AMPK inactivates ACC and, therefore, increases mitochondrial FAO [12]. 
It has been reported that AMPK decreases fatty acid synthesis by reducing the protein level of mature 
SREBP-1c [13]. AMPK is also known to increase the expression of proteins involved in fatty acid  
β-oxidation, including PPARʱ, PPARγ coactivator-1ʱ (PGC-1ʱ), CPT-1, and UCPs [14]. Therefore, 
AMPK has been suggested as a therapeutic target for dyslipidemia and obesity.  
Medicinal plants have been shown to prevent and treat obesity and associated metabolic disorders 
by  regulating  lipid  metabolism  [15].  For  example,  resveratrol,  (-)-epigallocatechin-3-gallate,  and 
berberine improve obesity by activating on AMPK [16–18]. Boesenbergia pandurata (Roxb.) Schltr. 
(Syn.  Kaempferia pandurata  Roxb.),  which  has  been  widely  used  as  a  medicinal  plant,  has  been 
reported to possess significant anti-inflammatory and anti-oxidative properties [19,20]. In the present 
study,  the  anti-obesity  effects  of  B.  pandurata  extract  (BPE)  and  its  molecular  mechanisms  were 
characterized in vitro and in vivo.  




2. Results and Discussion  
2.1. Adipogenesis, Hepatic Lipid Accumulation, and AMPK Activation 
Lipid  homeostasis  is  regulated  by  the  fine-tuning  of  lipid  synthesis  and  lipolysis,  which  are 
regulated by lipid regulatory enzymes in the peripheral tissues, such as adipose, liver, and muscle 
tissues [11]. To investigate the hypolipidemic effects of BPE in vitro, oil red O staining was performed 
to  evaluate  TG  accumulation  in  3T3-L1  adipocytes  and  in  insulin-induced  HepG2  hepatocytes. 
Treatment of 3T3-L1 adipocytes with BPE during adipogenesis markedly decreased TG accumulation 
(Figure 1A) without cytotoxicity (data not shown). BPE also inhibited TG accumulation in HepG2 
cells stimulated by insulin (Figure 1B) without cytotoxic effects (data not shown). 
Figure  1.  Effects  of  B.  pandurata  extract  (BPE)  on  triglyceride  accumulation  and  
AMP-activated  protein  kinase  (AMPK)  activation.  (A)  Anti-adipogenic  effects  of  BPE  in  
3T3-L1  adipocytes.  (B)  Inhibitory  effects  of  BPE  on  hepatic  lipid  accumulation  in  
insulin-induced  HepG2  cells.  Data  are  expressed  as  mean  ±   SD  from  three  independent 
experiments. 
# p < 0.05 (untreated control vs. MDI or insulin-treated control); * p < 0.05  
(BPE-treated cells vs. MDI or insulin-treated control). (C) Effects of BPE on the expression of 
lipid metabolism-related proteins in 3T3-L1 cells and HepG2 cells. (D) AMPK activation by 
BPE in 3T3-L1 cells and HepG2 cells. (E) Effects of an AMPK inhibitor, compound C, on the 
expression of PPARʱ and SREBP-1c. Each blot represents three independent experiments.  
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To determine the mechanism by which BPE reduced TG accumulation in 3T3-L1 adipocytes and 
HepG2 cells, western blot analysis was performed to evaluate the expression of proteins important in 
lipid metabolism. BPE treatment significantly attenuated the expression of adipogenic and lipogenic 
proteins  ACC,  FAS,  SREBP-1c,  and  PPARγ  in  3T3-L1  adipocytes  and  HepG2  hepatocytes.  This 




UCPs)  (Figure  1C).  These  results  suggest  that  BPE  reduces  TG  accumulation  in  two  ways:  by 
downregulating the expression of proteins involved in lipogenesis and by upregulating proteins in the 
FAO pathway. 
Because  AMPK  is  a  key  regulator  of  proteins  involved  in  lipogenesis  and  FAO  in  metabolic  
tissues [12], we investigated whether BPE activated AMPK by assessing its level of phosphorylation. 
BPE treatment drastically increased the phosphorylation of AMPK and ACC, a direct target of AMPK 
(Figure 1D). In addition, the effects of BPE on the expression of SREBP-1c and PPARʱ were reversed 
by compound C pretreatment, a potent AMPK inhibitor (Figure 1E). It has been reported that the 
phosphorylation of p38 mitogen-activated protein kinase (MAPK) by activated AMPK triggers PPARγ 
phosphorylation  and  inhibits  adipogenesis  [21].  BPE  treatment  drastically  increased  p38  MAPK 
phosphorylation (data not shown), suggesting that the inhibition of adipogenesis by BPE might be 
caused by PPARγ phosphorylation and reduced protein levels of mature SREBP-1c and PPARγ. These 
results collectively suggest that AMPK activation and regulation of lipid regulatory proteins mediate 
the hypolipidemic effects of BPE in 3T3-L1 adipocytes and HepG2 cells. 
In our previous study, we isolated panduratin A as an active compound from BPE and evaluated its 
anti-obesity  mechanisms  in  high-fat  diet  induced  obesity  [22].  Panduratin  A  stimulated  AMPK 
signaling, thereby increasing lipid catabolism and decreasing lipid accumulation. LKB1 is a kinase that 
lies upstream of AMPK. Specifically, panduratin A activated LKB1-dependent AMPK signaling as 
well as change of ADP/ATP ratio, which in turn regulated PPARʱ/ʴ and lipid regulatory proteins 
through  nuclear  translocation  of  the  AMPKʱ2  subunit  [22].  Although  BPE  used  in  this  research 
contained  8.0%  of  panduratin  A  as  a  major  bioactive  compound,  further  studies  are  necessary  to 
investigate interactions among the active compounds in BPE and upstream events of AMPK. 
2.2. Body Weight and Serum Lipid Parameters in HFD-Induced Obese Mice 
To determine whether BPE improves HFD-induced obesity in an animal model, diet-induced obese 
C57BL/6J mice received oral doses of BPE (200 mg/kg/day) for 8 weeks. Micro-CT data showed that 
the whole body fat accumulation was lower in the HFD-BPE group compared to the HFD control 
group (Figure 2A). The HFD-fed mice that were treated with BPE gained about 60% less weight than 
the mice in the HFD control group without altering the amount of food intake (Figure 2B). These 
results indicate that a reduction in body weight gain by oral BPE administration is not due to a change 
in food intake.  
Because diet-induced obesity alters serum lipids [1], we evaluated whether BPE could normalize 
these parameters. As shown in Figure 2C, BPE administration improved serum lipid profiles. Total 
cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride levels were reduced by 19%, 
55%, and 24%, respectively; however, no significant changes in the level of high-density lipoprotein 
(HDL) cholesterol were observed in BPE-treated mice. These data suggest that BPE might suppress 
obesity-induced hyperlipidemia by decreasing the serum lipid level. 
2.3. Fat Metabolism 
To examine whether a reduction in body weight gain by BPE was caused by a decrease in adiposity, 
fat pads were weighed after the mice were sacrificed. Reduced fat pad masses were observed in the 




epididymal (Epid) (14% less), perirenal (Peri) (25% less), and subcutaneous (S.C) (40% less) fat pads 
of the BPE-treated  group  (Figure  3A).  Histological analysis of the S.C fat pad  indicated that the  
BPE-induced reduction in fat pad mass was principally due to decreased adipocyte size (Figure 3B). 
These  results  indicate  that  BPE  reduces  fat  mass  by  attenuating  adipocyte  enlargement,  and  this 
suggests an anti-adipogenic effect of BPE. 
In addition to larger adipocytes, histological analysis of white adipose tissue (WAT) showed that 
clusters of small, nucleated cells were present in between the adipocytes from the HFD control group 
(Figure  3B).  These  clusters  of  nucleated  cells  implied  macrophage  infiltration  into  the  WAT. 
Macrophages  secrete  inflammatory  cytokines,  such  as  tumor  necrosis  factor-ʱ  (TNF-ʱ),  causing 
insulin resistance in the WAT [23]. However, BPE administration decreased the clusters of these small, 
nucleated cells in the WAT compared to the HFD control group (Figure 3B). It has been reported that 
BPE has strong anti-inflammatory activity [19], suggesting that the anti-inflammatory effects of BPE 
might  contribute  to  a  reduced  macrophage  infiltration  and  possible  treatment  of  dyslipidemia. 
However,  further  studies,  such  as  macrophage-specific  immunostaining  and  analysis  of 
proinflammatory  cytokine  levels,  should  be  conducted  to  determine  a  correlation  between  
anti-inflammatory effects and reduced macrophage infiltration. 
Figure 2. Effects of BPE on body weight and serum lipid parameters in an animal model. 
(A)  Computed  tomography  images  of  the  whole  body  of  C57BL/6J  mice  receiving  a  
high-fat diet (HFD) (HFD control) or a HFD with BPE (HFD-BPE). (B) Changes in body 
weight and food intake. Each point represents mean ±  SD (n = 8). (C) Serum levels of total 
cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Data are expressed as 
mean ± SD (n ≥ 5). * P < 0.05 (HFD control group vs. HFD-BPE group). 
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To determine whether the reduction in fat pad masses from the BPE-treated mice were accompanied 
by an altered expression of genes involved in lipid metabolism, proteins were prepared from Peri and 
S.C  fat  pads,  and  a  western  blot  analysis  was  performed.  Proteins  involved  in  lipogenesis  and 
adipogenesis, including ACC, FAS, SREBP-1c, and PPARγ, were reduced in these fat pads from  
BPE-treated  mice  (Figure  3C).  Conversely,  BPE  increased  the  expression  of  lipolytic  proteins, 
including PPARʱ, PGC-1ʱ, UCP1, and UCP2, in the WAT (Figure 3C). Consistent with the in vitro 
data, we found that BPE administration activated AMPK signaling in the Peri and S.C fat pads in this 
animal model (Figure 3D). Taken together, these results suggest that BPE reduces fat pad mass and 
adipocyte size by downregulating lipogenic proteins and upregulating FAO-related proteins. 
Figure  3.  Effects  of  BPE  on  fat  mass  and  expression  of  metabolic  proteins  in  white 
adipose  tissue  (WAT).  (A)  Fat  pad  masses  in  mice  fed  a  HFD  or  a  HFD  with  BPE  
(HFD-BPE). Data are expressed as mean ± SD (n ≥ 7). (B) Subcutaneous fat pads stained 
with  H&E  (magnification,  × 200).  (C)  Metabolic  protein  levels  in  perirenal  and 
subcutaneous fat pads. (D) AMPK activation by BPE in perirenal and subcutaneous fat 
pads.  BPE  denotes  the  HFD-BRE  group.  Each  blot  represents  8  mice  in  each  group.  
* P < 0.05 (HFD control group vs. HFD-BPE group). 
   
(A)  (B) 
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2.4. Hepatic Lipid Metabolism 
The development of nonalcoholic fatty liver disease is one of the most important characteristics of 
obesity [11]. Thus, the inhibitory effect of BPE on nonalcoholic fatty liver was evaluated by determining 
TG content in the livers of these animals. The gross appearance and histological analysis of the liver 




accumulated in the liver acini; however, hepatic TG content in the HFD-BPE group was significantly 
decreased by 50% compared to the HFD control mice (Figure 4A). These results indicate that BPE 
reduces hepatic lipid accumulation and may prevent the development of a nonalcoholic fatty liver. 
To understand the mechanism by which BPE decreased fat accumulation in the liver at a molecular 
level, western blot analysis was used to evaluate the expression of lipid metabolism-related proteins. 
As shown in Figure 4B, lipogenic protein levels of ACC, FAS, and SREBP-1c were significantly 
reduced  in  the  liver  of  BPE-treated  mice,  consistent  with  the  results  summarized  in  Figure  3C.  
In  addition,  the  expression  of  UCP2  was  significantly  increased  by  BPE  treatment;  however,  the 
expression of other FAO-related proteins, such as PPARʱ and CPT-1L, was modestly increased in the 
liver of BPE-treated mice (Figure 4B). Consistent with the in vitro AMPK activation, BPE increased 
the phosphorylation of AMPK and ACC in the liver of BPE-treated mice (Figure 4C). These results 
suggest  that  BPE  may  activate  AMPK  signaling  and  selectively  regulate  the  expression  of  lipid 
metabolism-related  proteins,  eventually  leading  to  both  the  suppression  of  lipogenesis  and  the 
degradation of fat. 
Figure 4. Hypolipidemic effects of BPE in the liver. (A) Gross appearance and weights of 
livers  from  the  HFD  and  HFD-BPE  groups.  Liver  tissues  were  stained  with  H&E 
(magnification, × 200) and hepatic triglyceride content was measured. Data are expressed 
as  mean  ±   SD  (n  =  7).  (B)  Hepatic  expression  of  lipid  metabolism-related  proteins. 
(C) AMPK activation by BPE in the liver. BPE denotes the HFD-BRE group. Each blot 
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3. Experimental Section  
3.1. Plant Material  
Rhizomes of B. pandurata were collected in Jakarta, Indonesia and identified by Dr. Nam-In Baek 
from the Department of Oriental Medicinal Materials and Processing at Kyunghee University (Yongin, 
Korea).  A  specimen  voucher  has  been  deposited  in  the  Department  of  Biotechnology  at  Yonsei 
University (Seoul, Korea). The dried B. pandurata rhizomes were ground and extracted with 95% 
ethanol,  and  BPE  was obtained by  filtration followed by solvent evaporation  (yield  12.0%). BPE 
contained 8.0% of panduratin A as a bioactive compound [22]. 
3.2. Chemical Reagents 
Insulin, 3-isobutyl-1-methylxanthine (IBMX), and dexamethasone (DEX) were purchased from Sigma 
(St  Louis,  MO,  USA).  Antibodies  against  phosphorylated  ACC  (Ser79),  AMPK,  phosphorylated 
AMPK (Thr172), and PPARγ were purchased from Cell Signaling Technology (Beverly, MA, USA). 
An antibody against ʱ-tubulin was purchased from Calbiochem (San Diego, CA, USA). Antibodies 
against  ACC,  FAS,  SREBP-1c  (amino-terminal  fragment),  PPARʱ,  PGC-1ʱ,  UCP1,  UCP2,  and  
CPT-1L (liver form) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).  
3.3. Cell Culture and Differentiation 
3T3-L1  preadipocytes  and  HepG2  hepatocytes  were  obtained  from  American  Type  Culture 
Collection (ATCC; Manassas, VA, USA). They were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with penicillin (120 units/mL), streptomycin (75 μg/mL), 10% bovine calf 
serum (BCS; for the 3T3-L1 preadipocytes) and 10% fetal bovine serum (FBS) (Welgene; Daegu, 
Korea) in an atmosphere of 5% CO2 at 37 ° C. Differentiation medium (MDI; 0.5 mM IBMX, 0.2 μM 
DEX,  and  1.7  μM  insulin  in  DMEM  medium  with  10%  FBS)  was  added  to  confluent  3T3-L1 
preadipocytes with BPE (5–25 μg/mL) for 8 days. The cells were then differentiated as previously 
described [24]. Induction of hepatic lipid accumulation in HepG2 cells was established by pretreatment 
with  insulin  (1  μM)  for  12  h  [25],  and  insulin-induced  HepG2  cells were  then treated  with  BPE  
(5–25 μg/mL) for another 12 h. The extent of adipogenesis and hepatic TG accumulation was determined 
by oil Red O staining. 
3.4. Animal Experiments 
Sixteen male C57BL/6J mice (DooYeol Biotech, Seoul, Korea) at 4 weeks of age were housed in a 
controlled environment (25 ±  2 
○C, 55 ±  5% relative humidity, a 12 h light-dark cycle). Throughout the 
experiment, the mice were allowed free access to food and tap water. After acclimatization for 1 week, 
all mice were fed a HFD (Rodent diet D12451; Research Diets, New Brunswick, NJ, USA). This diet 
contained 45% of its energy from fat, 35% from carbohydrates, and 20% from protein. After 7 weeks 
of dietary manipulation to induce obesity, the animals were divided equally into two groups of 8. Mice 
in each group were either given BPE (HFD-BPE group) or vehicle alone (HFD group). BPE was 




BPE at a dose of 200 mg/kg/day by oral sonde for 8 weeks. Mice in the HFD group were given an 
equal volume of CMC. Water, food intake, and body weight were measured twice per week throughout 
the experiment. 
At the end of the 8-week, oral-administration period, all mice were sacrificed with diethyl ether 
after an overnight fast. Their fat pads and livers were removed, weighed, and frozen in liquid nitrogen. 
Micro-computed  tomography  (micro-CT)  experiments  were  performed  with  an  animal  positron 
emission  tomography  (PET)/CT/single  photon  emission  computed  tomography  (SPECT)  system 
(INVEON, Siemens, Houston, TX, USA) at the Korea Basic Science Institute in Ochang. This study 
adhered  to  the  Guide  for  the  Care  and  Use  of  Laboratory  Animals  developed  by  the  Institute  of 
Laboratory Animal Resources of the National Research Council. It was approved by the Institutional 
Animal Care and Use Committee of Yonsei University in Seoul, Korea. 
3.5. Histological and Biochemical Analysis 
White adipose tissue (WAT) and livers were obtained from the HFD control and HFD-BPE groups 
and  embedded  in  tissue-freezing  medium  (Leica,  Wetzlar,  Germany),  fixed  as  previously  
described [22]. After fixation, they were stained with hematoxylin and eosin (H&E) and analyzed for 
hepatic lipid accumulation and adipocyte size with an Eclipse TE2000U Inverted Microscope with 
twin CCD cameras (magnification, × 200; Nikon, Tokyo, Japan). 
Blood was collected by heart puncture from all mice and held at room temperature for 1 h. Serum 
was then prepared by centrifugation at 4,000 rpm for 15 min and stored at −70 
○C until analysis. 
Serum lipid profiles were determined with a commercial enzyme-linked immunosorbent assay (ELISA) 
kit from R&D Systems (Minneapolis, MN, USA). 
3.6. Measurement of Hepatic Triglyceride Content 
To  determine  hepatic  TG  levels,  liver  homogenates  were  mixed  with  a  chloroform-methanol 
solution (chloroform-methanol, 2:1). The mixture was inverted and shaken for 1 h and then centrifuged 
at 12,000 rpm for another 15 min. The bottom layer was collected and re-suspended to analyze TG 
content. Total lipids were measured with the enzymatic hydrolysis method. 
3.7. Western Blot Analysis 
WAT and liver specimens (approximately 100 mg each) from the HFD control and HFD-BPE 
groups were homogenized with lysis buffer supplemented with a protease inhibitor cocktail (Sigma). 
After treatment with BPE (5–25 μg/mL for 48 h), 3T3-L1 adipocytes and HepG2 hepatocytes were 
lysed, and whole cell lysates were collected. To measure the activation of AMPK signaling, we treated 
3T3-L1 adipocytes and HepG2 cells with BPE (5–25 μg/mL) for 1 h, and whole cell lysates were 
collected.  To  evaluate  the  inhibitory  effects  of  compound  C  on  the  expression of  SREBP-1c  and 
PPARʱ, we pretreated cells with compound C for 30 min. Protein concentrations were measured by 
the Bradford assay. Western blot analysis was performed according to a standard procedure using 




system (Amersham Biosciences, Little Chalfont, UK) and visualized with a LuminoImager (LAS-3000 
Bio Imaging Analysis System; Fuji Film Co., Tokyo, Japan). 
3.8. Statistical Analysis 
All experiments were repeated at least three times, and each experiment was performed in triplicate. 
Results are presented as mean ±  standard deviation (SD). Statistical analyses were performed using 
SPSS 9.0 (SPSS Inc., Chicago, IL, USA). Group differences were assessed by one-way analysis of 
variance  (ANOVA)  followed  by  a  Duncan’s  test. 
#  p  <  0.05  and *  p  <  0.05  was  considered  
statistically significant.  
4. Conclusions  
The  active constituents  in  B.  pandurata  rhizomes  that  mediate  the  anti-obesity  effects  are  still 
unknown. It has been reported that various active compounds, such as flavones and cyclohexenyl 
chalcone  derivatives,  are  present  in  B.  pandurata  rhizomes,  and  these  compounds  represent  
anti-oxidative  and  anti-inflammatory  activities  [20,26].  We  previously  reported  that  panduratin  A,  
a major active constituent in B. pandurata rhizomes, shows strong anti-oxidative and anti-inflammatory 
activities  [19,20].  Thus,  studies  evaluating  the  metabolic  effects  and  molecular  mechanisms  of 
panduratin A on obesity are under investigation. 
The present study is the first to demonstrate that BPE administration blocks HFD-induced weight 
gain, normalizes serum lipid parameters, and attenuates excessive lipid accumulation in the WAT and 
liver  of  mice  by  activating  AMPK  and  regulating  the  expression  of  proteins  involved  in  lipid 
metabolism. Although the molecular mechanisms by which BPE exerts its anti-obesity effects remain 
to be elucidated, BPE shows potential as a novel, natural agent for the prevention and treatment of 
obesity and associated fatty liver disease. 
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